Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/olmesartan-medoxomil/rosuvastatin - Daewoong Pharmaceutical

Next Previous
Drug Profile

Amlodipine/olmesartan-medoxomil/rosuvastatin - Daewoong Pharmaceutical

Alternative Names: Amlodipine besylate/olmersartan medoxomil/rosuvastatin calcium; Amlodipine/olmesartan/rosuvastatin; DWJ1351; Olmersartan medoxomil/amlodipine besilate/rosuvastatin calcium; Olmersartan medoxomil/amlodipine besylate/rosuvastatin calcium; Olmesartan/amlodipine/rosuvastatin; Olomax

Latest Information Update: 25 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Cardiovascular therapies; Dihydropyridines; Fluorobenzenes; Imidazoles; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia; Hypertension

Most Recent Events

  • 19 Jul 2019 Daewoong Pharmaceutical completes a phase III trial in Hyperlipidaemia and Hypertension in South Korea (PO) (NCT03009487)
  • 19 Jul 2019 Efficacy data from a phase III trial in Hypertension and Hyperlipidaemia released by Daewoong Pharmaceutical
  • 26 Jan 2018 Daewoong Pharmaceutical completes enrolment in a phase I trial in Healthy volunteers in South Korea (NCT03753477)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top